Ratings Jointown Pharmaceutical Group Co., Ltd

Equities

600998

CNE100000W45

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
8.54 ^CNY	+0.95%		+6.09%	+21.83%

Apr. 08	Jointown Pharmaceutical Sets Up Joint AI Lab with Peking University's Wuhan Campus	MT
2023	Jiuzhoutong Pharmaceutical Investment Co., Ltd. announced that it expects to receive CNY 10.9100689 billion in funding from Jointown Pharmaceutical Group Co., Ltd	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company shows low valuation levels, with an enterprise value at 0.25 times its sales.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+21.83%	4.45B	B+
MCKESSON CORPORATION	+13.36%	68.18B	C+
CARDINAL HEALTH, INC.	+7.33%	25.78B	C+
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+6.34%	7.99B	B
SINOPHARM GROUP CO. LTD.	-2.79%	7.88B	C
HUADONG MEDICINE CO., LTD	-24.02%	7.62B	B-
EBOS GROUP LIMITED	-2.28%	3.89B	B-
GALENICA AG	-3.51%	3.82B	B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+25.02%	3.69B	C+
MEDIPAL HOLDINGS CORPORATION	+3.28%	3.24B	C

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes